Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide


The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95–110 mm Hg). Patients (n = 1098) completing two randomised, double-blind trials of irbesartan alone, HCTZ alone, irbesartan/HCTZ combinations, or placebo, took 1 year of open-label therapy starting with irbesartan 75 mg/HCTZ 12.5 mg once daily. If target blood pressure (BP) (<140/<90 mm hg) was not achieved, the dose was titrated sequentially at 2- to 4-week intervals to irbesartan 150 mg/hctz 12.5 mg, then to irbesartan 300 mg/hctz 25 mg. if necessary, adjunctive therapies were added. mean changes in trough seated systolic bp/sedbp at months 2, 6, and 12 were −19.1/−14.2 mm hg (n = 941), −20.7/ −15.7 mm Hg (n = 948), and −20.6/−15.6 mm Hg (n = 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP <90 mm hg) ranged from 75–85% and total responder rates (normalised or 10 mm hg trough sedbp reduction) ranged from 81–91%, while target bp was achieved in 65–75% of patients. at all time-points, most patients (87%) were receiving irbesartan/hctz alone. eighty-two patients (7.5%) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. there were no reports of serious adverse events related to study medication. long-term therapy with irbesartan/hctz is safe, well tolerated, and maintains normalised bp in >80% of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Raskin, P., Guthrie, R., Flack, J. et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 13, 683–687 (1999).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links